STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	TALIGLUCERASE ALFA
PRONUNCIATION	tal" i gloo' ser ase al' fa
THERAPEUTIC CLAIM	Treatment of Gaucher disease

CHEMICAL NAMES

1. Ceramidase, glucosyl-

2. L-glutamyl-L-phenylalanyl-[495(*497*)-L-histidine(R>H)]human glucosylceramidase (beta-glucocerebrosidase) peptide with L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-threonyl-L-methionine, glycosylated peptide *1-506*

STRUCTURAL FORMULA

```
EFARPCIPKS  FGYSSVVCVC  NATYCDSFDP  PTFPALGTFS  RYESTRSGRR   50
MELSMGPIQA  NHTGTGLLLT  LQPEQKFQKV  KGFGGAMTDA  AALNILALSP  100
PAQNLLLKSY  FSEEGIGYNI  IRVPMASCDF  SIRTYTYADT  PDDFQLHNFS  150
LPEEDTKLKI  PLIHRALQLA  QRPVSLLASP  WTSPTWLKTN  GAVNGKGSLK  200
GQPGDIYHQT  WARYFVKFLD  AYAEHKLQFW  AVTAENEPSA  GLLSGYPFQC  250
LGFTPEHQRD  FIARDLGPTL  ANSTHHNVRL  LMLDDQRLLL  PHWAKVVLTD  300
PEAAKYVHGI  AVHWYLDFLA  PAKATLGETH  RLFPNTMLFA  SEACVGSKFW  350
EQSVRLGSWD  RGMQYSHSII  TNLLYHVVGW  TDWNLALNPE  GGPNWVRNFV  400
DSPIIVDITK  DTFYKQPMFY  HLGHFSKFIP  EGSQRVGLVA  SQKNDLDAVA  450
LMHPDGSAVV  VVLNRSSKDV  PLTIKDPAVG  FLETISPGYS  IHTYLWHRQD  500
LLVDTM                                                     506
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

6-18 *20-25*

Glycosylation sites N / Sites de glycosylation N / Posiciones de glicosilación N

Asn-*21* Asn-*61* Asn-*148* Asn-*272*

```
α-Man→6 ┐                    R→6 ┐
        ├ β-Man→4-β-Gl-N→4 ┤ β-Gl-N→peptide
α-Man→3 ┘                    ┘
R'→2 ┘
```

R = α-Fuc or H ; R' = β-Xyl or H

Fuc = 6-deoxy-D-galactopyranosyl
Gl-*N* = 2-(acetylamino)-2-deoxy-D-glucopyranosyl
Man = D-mannopyranosyl
Xyl = D-xylopyranosyl

MOLECULAR FORMULA	$C_{2580}H_{3918}N_{680}O_{727}S_{17}$
MOLECULAR WEIGHT	56.64 kDa (peptide)
TRADEMARK	None as yet
MANUFACTURER	Protalix Biotherapeutics, Inc.
CODE DESIGNATION	prGCD
CAS REGISTRY NUMBER	37228-64-1